ImmunityBio Initiates Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma
核心洞察
ImmunityBio's stock surged following the launch of a Phase 1 trial (QUILT 106) in South Africa for CD19 (搜索) t-haNK cell therapy targeting non-Hodgkin lymphoma (搜索).
The trial will evaluate the novel therapy as a standalone treatment and in combination with rituximab, aiming to enroll up to 100 patients by early 2025.
This initiative reflects ImmunityBio's strategy to use CAR-NK technology to address unmet needs in liquid tumors, with initial data expected by the second half of 2025.
ImmunityBio has initiated a Phase 1 clinical trial (QUILT 106) in South Africa to evaluate its CD19 (搜索)-targeted t-haNK cell therapy for the treatment of non-Hodgkin lymphoma (搜索). The trial represents ImmunityBio's first natural killer cell-based trial in the region.
The QUILT 106 study aims to enroll up to 100 patients by early 2025 and will assess the safety and efficacy of the CD19 (搜索) t-haNK cell therapy both as a monotherapy and in combination with rituximab. This approach seeks to address gaps where existing therapies have limitations, particularly in liquid tumors.
Patrick Soon-Shiong, executive chairman of ImmunityBio, highlighted the significance of the trial in addressing unmet medical needs in Sub-Saharan Africa. The trial could potentially set a precedent for future research and treatment accessibility in underserved areas.
By leveraging CAR-NK technology, ImmunityBio aims to generate critical data by the second half of 2025 that could reshape how non-Hodgkin lymphoma (搜索) is treated. The company is positioning itself as a disruptor in the cancer therapy space.